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The London School of Medicine and Dentistry, London, UKAs gene transfer with adeno-associated virus (AAV) vectors is
starting to enter clinical practice, this review examines the
impact of vector capsid choice in liver-directed gene transfer
for hemophilia. Given that there are multiple clinical trials
completed and ongoing in this ﬁeld, it is important to review
the clinical evidence, particularly as a range of AAV-vector
serotypes including AAV2, AAV5, AAV8, and AAV10 have
been tested. Although there have been a number of successful
trials, the development of two investigational AAV vectors
for hemophilia B has been discontinued because they did not
meet efﬁcacy and/or safety expectations. Whether this differ-
ence between success and failure of gene transfer approaches
reﬂects capsid choice, vector design, manufacturing system,
or other variables is a question of great interest. Here, we
examine the body of evidence across trials to determine the
possible inﬂuences of serotype choice on key clinical outcomes
such as safety, vector clearance, treatment eligibility, occur-
rence of transaminase elevations, activation of capsid-directed
cytotoxic T cell responses, and clinical efﬁcacy. In summary,
gene transfer requires a balance between achieving sufﬁcient
transgene expression and minimizing destructive immune re-
sponses, which may be affected by AAV-vector serotype choice.https://doi.org/10.1016/j.omtm.2019.08.015.
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E-mail: ummdswp@med.umich.eduTherapies employing gene transfer using adeno-associated virus
(AAV) vectors are being fast-tracked for clinical approval for retinal
disease, congestive heart failure, hemophilia A and B, X-linked myo-
tubular myopathy, glioblastoma, glioma, and spinal muscular atro-
phy.1,2 The focus of this review will be liver-directed AAV gene
therapy for hemophilia, in which there are a number of completed
or ongoing phase 1 and 2 trials and phase 3 trials that are recruiting.3
Given that there are multiple clinical trials in this ﬁeld, it is important
to review the clinical evidence, particularly as a range of AAV-vector
serotypes including AAV2, AAV5, AAV8, and AAV10 have been
tested. In addition, other AAV serotypes such as AAVhu37, a
Clade E AAV that is closely related to AAV8,4 have been examined
in non-human primate (NHP) models.5 Interestingly, the develop-
ment of two investigational therapies, DTX101 (rAAV10-hFIX) and
BAX335 (AAV8-hFIX), were stopped as they failed to meet manufac-
turer expectations in terms of efﬁcacy and/or safety. Whether these170 Molecular Therapy: Methods & Clinical Development Vol. 15 Decem
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reﬂect capsid choice, vector design, manufacturing system, or
other variables is open to question. Although vector design and
manufacturing/production systems are beyond the scope of this re-
view, we will examine the impact of capsid choice by exploring
AAV serotypes, the basis for serotype distinction, tropism, transduc-
tion efﬁcacy, vector shedding, immune responses to AAV, and the
impact of pre-existing neutralizing antibodies (NAb) on transduction
efﬁcacy to summarize what is known and identify areas that require
further investigation.AAV Capsid Serotypes
The AAV genome includes rep and cap genes that encode seven pro-
teins.6 The rep gene encodes four non-structural proteins (Rep78,
Rep68, Rep 52, and Rep 40), involved with replication, transcriptional
control, integration, and encapsidation. The products of the three cap
genes (Vp1–3) combine as 50 Vp3, ﬁve Vp1, and ﬁve Vp2 proteins to
form the capsid.6,7 Capsid assembly is assisted by the assembly-acti-
vating protein, a non-structural protein encoded within the cap
gene, which promotes capsid stability and interactions between the
capsid proteins.8 The AAV capsid includes a core eight-stranded
b-barrel motif with large loop insertions between the b strands.9
The common structural features across serotypes are depicted in Fig-
ure 1A,9,10 suggesting that these features may have speciﬁc functional
activities (e.g., tissue trophism and cellular transduction) although
variable regions within these structures between serotypes may confer
distinct serotype-speciﬁc functional features as vectors for gene trans-
fer and affect immunogenicity.
Currently, 13 AAV serotypes have been identiﬁed, which are differen-
tiated based on surface antigen expression and amino acid sequence
differences.7 AAV have been separated into clades A–F, on the basis
of shared serologic and functional attributes, as well as two separate
clonal isolates (AAV5 and AAV4) that exhibit greater differencesber 2019 ª 2019 The Authors.
://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. AAV Capsids Share Some Common Structural Features across
Serotypes
(A) AAV1 showing common capsid structure features shared with other serotypes.
The color coding from blue-green-yellow-red represents the surface topology with
the darkest blue representing the lowest areas and the red representing the pro-
truding areas of capsid. (B) Location of the nine variable regions (VRs) in the AAV
capsid. Figure reproduced from Tseng and Agbandje-McKenna.10
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Reviewcompared with the other serotypes (Figure 2).7 AAV5 is the most
phylogenetically distinct as it shares only 58% capsid homology
with AAV2 and AAV8 and 57% homology with AAV10 (Figure 2).11
In contrast, the other serotypes commonly used in gene transfer share
greater homology (e.g., AAV2 shares 83% homology with AAV8 and
84% homology with AAV10).11 The variance in structure includes
conformational differences in regions associated with transduction
efﬁcacy and antigenicity, which may be important in terms of differ-
ences in tissue tropism, antigenicity, and the likelihood of cross-reac-
tive immunogenicity between serotypes.7,9,10,12
Does AAV-Vector Capsid Affect Tissue Tropism?
Tropism can reduce off-target effects by limiting transduction to a
particular tissue or cell type andmay impact efﬁcacy by concentrating
cell transduction in a relevant tissue. Tissue tropism reﬂects the spe-
ciﬁc interactions between structures on the AAV-vector capsid that
differ between serotypes and glycans (Table 1).13 The initial binding
of many AAV serotypes is via primary receptors including glycans
and proteoglycans such as heparan sulfate that are widely expressed
in different tissues.14 This initial binding is followed by interactions
with secondary membrane protein receptors that facilitate internali-
zation.14 A range of secondary receptors has been reported, including
the ﬁbroblast growth factor receptor 1 (FGFR1 and alphaV-beta5 in-
tegrin) for AAV2,15 hepatocyte growth factor receptor (c-MET) for
AAV216 and AAV3,17 and platelet-derived growth factor receptorMolecular Thefor AAV5.13 Recently, the protein receptor KIAA0319L (hereafter
AAVR) has been identiﬁed as critical for the entry of numerous
AAV serotypes including AAV1, AAV2, AAV3B, AAV5, AAV6,
AAV8, and AAV9.14 Importantly, the interactions between AAV se-
rotypes and their primary and secondary receptors are likely to affect
tissue speciﬁcity/tropism (Table 1).18 In mice, AAV serotypes 1–9
show overlapping but distinct tissue expression patterns: skeletal
muscle (AAV 1–9), liver (AAV 1–3 and 5–9), heart (AAV4 and
6–9), lung (AAV4 and 6–9), brain (AAV 8–9), and testes
(AAV9).19 Notably, here are species-speciﬁc differences in AAV
tropism between mice and nonhuman primates,20, which raises the
question of generalizability of ﬁndings across species as well as their
relevance for humans.
Given the difﬁculties in justifying multiple biopsies in the clinical
setting, vector biodistribution has not been reported in currently pub-
lished trials21–25 and thus data demonstrating tropism proﬁles in
humans is not available. If less invasive, non-biopsy techniques could
be developed to assess AAV-vector tropism, this is an area that could
be further investigated in future trials. In the absence of such informa-
tion in humans, tissue-speciﬁc promoters are frequently incorporated
into vectors to limit the expression of the transgene to a particular
target tissue. For example, recent clinical trials employing systemic
administration to target the liver utilize vectors with liver-speciﬁc
promoters: e.g., AAV5-hFIXWT (AMT-060), AAV5-hFIXPadua
(AMT-061), SPK-9001, AAV5-hFVIII-SQ (Valoctocogene Roxapar-
vovec), and scAAV2/8-LP1-hFIXco.23–26
Clinical Considerations
AAV-Vector Efficacy
Differences in liver transduction efﬁcacy have been demonstrated in
animal models with AAV7 and AAV8-based vectors being approxi-
mately 10- to 100-foldmore efﬁcient thanAAV2- orAAV5-based vec-
tors,27,28 although AAV tropism in mice is likely to be different from
that inNHPandhumans. Interestingly, this difference does not appear
to reﬂect the ability of the different serotypes to enter hepatocytes, but
insteadmay reﬂectmore rapid uncoating and conversion of the single-
stranded vector DNA into duplex DNA that is transcriptionally
active.27,29 In theory, a more effective vector could be administered
at a lower dose compared with a less effective serotype. Administering
a lower dose could have potential beneﬁts in terms of reduced immu-
nogenicity. In practical terms, however, a range of factors such as host
immunity to the serotype, the quality of vector manufacturing, and
transgene activity will also impact the balance between vector dose
and the clinical outcomes of gene transfer.
AAV-Vector Clearance
In the ﬁeld of virology, the term “shedding” is typically used to
describe the release of infectious virus from host cells following infec-
tion. In the setting of gene therapy, vector shedding is monitored due
to the potential risks of vertical transmission to progeny from the
presence of AAV vector in semen and from horizontal transmission
to close contacts or the wider community via AAV-vector shedding
into other body ﬂuids. AAV vectors are designed to be replicationrapy: Methods & Clinical Development Vol. 15 December 2019 171
Figure 2. Phylogenetic Relationships among AAV
Serotypes
Figure reproduced Drouin and Agbandje-McKenna.7
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the primary administration. Monitoring of vector shedding, there-
fore, represents a measure of clearance of the vector from the body
rather than active reproduction of the virus, and, as such, may reﬂect
a number of variables including dose, route of administration, target
organ,30 and potentially interindividual differences. It is important to
note that current shedding assays measure vector DNA, so they are
unable to distinguish between vector particles versus different forms
of DNA (free, episomal, or integrated). Therefore, the detection of
vector DNA in body ﬂuids does not necessarily imply an infectious
risk. Indeed, in NHP, AAV-vector DNA was detected in all body
ﬂuids for up to 6 days after vector transfer, whereas complete
AAV-vector particles were only detected in serum for 48–72 h post
transfer.31
In clinical trials, transient vector shedding was observed for AAV5,
AAV2/8, and SPK-9001, although shedding was still detectable in
some individuals at week 26 in whole blood for AAV5-hFIXWT
2  1013 gc/kg, week 52 in whole blood for AAV5-hFIXWT
5 1012, and week 52 in feces and whole blood for AAV5-hFVIII-SQ
(Table 2). Shedding into semen is transient and germ-line transmis-
sion has not been observed in animal studies;30,32 however, physicians
should inform individuals that barrier contraception should be prac-
ticed as a precaution until clearance of vector DNA in semen is
conﬁrmed. It is of interest that vector shedding was more prolonged
for AAV5-hFVIII-SQ than AAV5-hFIXWT, which may reﬂect theTable 1. Relationships between AAV Serotype Receptor Usage and
Tropism are supported by references13,14,18,20,59–61
Glycan Receptor Serotype
Usage AAV Serotype Impact on Tropism
Heparan sulfate
proteoglycan
AAV2, AAV3, AAV6,
and AAV13
AAV2 muscle cell
interactions
a2–3 and a2–6 N-linked
sialic acid (SIA)
AAV1, AAV4, AAV5,
and AAV6
AAV5 airway epithelial
cell interactions
Laminin receptor AAV8
widely expressed on
tissues targeted by AAV8
including heart, liver, and
skeletal muscle
Terminal N-linked
galactose of SIA
AAV9
may enable the ability of
AAV9 to cross the
blood-brain barrier and
transduce neural tissues
AAV receptor (AAVR,
KIAA0319L)
AAV1, AAV2, AAV3B,
AAV5, AAV6, AAV8,
and AAV9
AAVR is critical for the
entry of numerous
AAV serotypes
172 Molecular Therapy: Methods & Clinical Development Vol. 15 December 2019higher doses of AAV5-hFVIII-SQ administered.
SPK-9001 and scAAV2/8-LP1-hFIXco were
administered at the lowest doses and appearedto have the most transient AAV-vector shedding proﬁle, which also
supports a potential dose effect although further investigation is
required.
Immune Responses to AAV Vectors
There are two main branches of the adaptive immune system that
appear to have the most impact on AAV-vector gene transfer—
humoral and cell-mediated immunity. The humoral immune
response results in the generation of vector-serotype-speciﬁc anti-
bodies, some of which may be neutralizing. Pre-existing neutralizing
antibodies to AAV vectors, which may reﬂect natural exposure to
wild-type AAV serotypes or prior AAV-vector exposure, can reduce
or prevent successful transduction and thereby impair therapeutic
efﬁcacy. Following AAV-vector-based gene transfer, high-titer
neutralizing antibodies against the AAV-vector capsid are generated.
While these antibodies formed following gene therapy will have no
impact on the success of the initial gene transfer, they have implica-
tions for readministration of the same serotype and potentially, cross-
reactive serotypes. Approaches to circumventing this issue include the
use of alternative non-cross-reacting AAV-vector serotypes, which
while demonstrated successfully with AAV5 and AAV1 in animal
models33 can be challenging as NAb can cross-react across AAV-
vector serotypes, and immunoadsorption/plasmapheresis to reduce
levels of circulating NAb.34
Cellular immunity includes cytotoxic T cell responses that are usually
measured using an enzyme-linked immunosorbent spot (ELISPOT)
assay of interferon-g (IFN-g) production, which will typically
develop 4–12 weeks after gene transfer. One study suggests, however,
that memory CD8 cytotoxic T cells in AAV seropositive donor pe-
ripheral-blood mononuclear cells (PBMCs) secrete tumor necrosis
factor alpha (TNF-a) in response to AAV capsid peptides rather
than IFN-g.35 Therefore, by focusing on IFN-g responses, trials
may be overlooking key CD8 T cell mediated immune responses to
AAV-vector capsids. If conﬁrmed, this may explain some of the
discrepancies observed between IFN-g ELISPOT responses, liver
transaminase elevations, and loss of factor activity that are described
in the next section.
Murine studies indicate that the development of cytotoxic T cell re-
sponses against AAV vectors requires innate immune sensing via
Toll-like receptor (TLR) 9 on plasmacytoid dendritic cells.36 TLR 9
appears to sense the vector genome, as self-complementary AAV2
vectors induced stronger TLR 9 mediated innate responses than sin-
gle-stranded AAV2 vectors in mice.37 There is evidence that another
TLR (TLR 2) is key for sensing AAV-vector capsid antigens.38 As we
Table 2. Vector Shedding in Clinical Trials of Liver-Directed Gene Therapy
Serotype
SPK-9001 (Serotype
Unknown) 5  1011 gc/kg25
scAAV2/8-LP1-hFIXco
2  1012 gc/kg22
AAV5-hFIXWT (AMT-060)
5  1012 gc/kg23
AAV5-hFIXWT (AMT-060)
2  1013 gc/kg23
AAV5-hFVIII-SQ (Valoctocogene
Roxaparvovec) 6  1013 gc/kg24
SPK-100 AAV2/8 AAV5 AAV5 AAV5
Period of Vector Shedding, Weeks (Maximum or Range)
Nasal secretions not reported not reported 18 12 not reported
Saliva 4–6 2 20 16 40–52
Feces not reported 2 16 20 present to ﬁnal assessment (week 52)
Urine 2–8 not reported 11 22 6–28
Semen 4–12 2 48 22 36–56
Whole blood 22–42 (PBMCs) 2 (plasma)
present to ﬁnal
assessment (week 52)
present to ﬁnal
assessment (week 26)
present to ﬁnal assessment (week 52)
Gc, genome copies; PBMCs, peripheral-blood mononuclear cells.
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ences in immune responses to AAV vectors in clinical trials. As more
information emerges on the interactions between different AAV sero-
types and the innate and adaptive immune systems, the reasons for
these differences may become clearer. Given the potential for TLRs
to recognize differences in AAV-vector genomes, as well as vector
capsid, other factors in addition to AAV serotype, such as the use
of self-complementary AAV vectors or codon optimization, may
affect immunogenicity.
The Impact of AAV-Vector Serotype on Immune Responses and
Liver Toxicity/Loss of Efficacy
AAV-vector-mediated liver toxicity indicated by alanine aminotrans-
ferase (ALT) elevations and activation of capsid-speciﬁc CD8 T cells
has been associated with subsequent decline in FIX and FVIII activity
in clinical trials with AAV2, AAV8, and AAV10 (Tables 3 and 4).39–41
In contrast to these ﬁndings, with AAV5-based vectors, there was no
observed connection between ALT or aspartate aminotransferase
(AST) elevations, cytotoxic T cell responses, and reduction of factor
activity (Tables 3 and 4) in clinical trials to date (0/10 participants
with AAV5hFIX and 1/8 participants with AAV5hFVIII-SQ).23,24
The lack of T cell responses and maintenance of factor activity in
the presence of transaminitis in both AAV5-vector-based trials in
hemophilia23,24 and similar lack of immune response in the porphyria
trial42 provide initial indications of serotype-speciﬁc differences in the
generation of capsid-speciﬁc T cell responses, although this will need
to be conﬁrmed in further studies (Tables 3 and 4). In addition, this
evidence, along with ﬁndings of inconsistent relationships between
transaminase elevation and T cell responses from the scAAV2/
8-LP1-hFIXco trial, suggests that ALT and/or AST elevations may
not always signal the destruction of transduced hepatocytes.21,23
The best way to control immune responses to AAV vectors remains to
be determined. Clinically, the use of prophylactic versus on-demand
immunosuppression, high-activity transgenes that enable lower doses
of vector to be used, and engineering of the capsid surface to reduce
immunogenicity have been proposed and are being investigated. In
terms of liver toxicity, there is a need to clarify the relative impactMolecular Theof immune responses, the potential for AAV vectors to induce direct
hepatocyte stress responses (whether to AAV-vector capsid or trans-
gene), and the potential for toxicity related to concomitant drug use
(e.g., efavirenz for HIV infection).43 Therefore, it should be consid-
ered whether it would be advisable to collect liver tissue biopsies in
future trials so that this issue can be clariﬁed.
AAV-Vector Serotypes and Neutralizing Antibodies
Anti-AAV NAb have historically been believed to diminish the efﬁ-
cacy of AAV-based therapies delivered systemically in humans, on
the basis of results from preclinical and clinical trials utilizing
AAV2 and AAV8. In humans, pre-existing NAb at titers as low as
1:17 for AAV244 and 1:1 for the bioengineered capsid AAV-
Spark10025 were associated with reduced, or abrogated, therapeutic
efﬁcacy (Table 5). These observations have led to the exclusion of sub-
jects with even low levels of anti-AAV NAb from the majority of
AAV-vector-based gene therapy trials up until now. In contrast to
other AAV-vector serotypes, successful liver transduction was
achieved with AAV5 vector in both NHP and humans with pre-exist-
ing anti-AAV5 NAb titers up to 1:1,030 for NHP and 1:340 for
humans (Table 6).23,45,46 Based on data such as this, gene transfer
using AAV5 vectors is being investigated in participants with titers
of NAbs to the serotype in trials in hemophilia A and B.47,48
There is a clear need for a standardized approach for measuring NAbs,
so that the cut offs for titers that could cause a clinically relevant impair-
ment of gene transfer can be identiﬁed. Importantly, such cut-offs will
likely need to be vector serotype and assay speciﬁc.AsTable 5 indicates,
clinical trials include different assays such as inhibition of trans-
duction and direct measurement of antibody titers as well as different
cut-offs for demonstrating positivity, so it is impossible to compare
ﬁndings between studies. An aligned approach to deﬁning clinically
relevant titers will be key as gene therapy enters clinical practice.
Due to the high degree of conservation in the amino acid sequence
among AAVs,49 anti-AAV antibodies show cross reactivity with a
wide range of serotypes.50 AAV2 has the highest seroprevalence of
NAb in the general population,50 which may make this serotype mostrapy: Methods & Clinical Development Vol. 15 December 2019 173
Table 3. Immunogenicity of Different AAV Gene-Transfer Preparations for Hemophilia B
Parameter AAVrh10FIX62,67 rAAV2hFIX44 BAX 33563,64 scAAV2/8-LP1-hFIXco21,22 SPK-9001 (AAV-FIX)25 AAV5hFIX23
Serotype AAV10 AAV2 AAV8 AAV2/8 not reported AAV5
Dose, gc/kg (n)
Co. 1: 1.6  1012 (3)
2  1012 (2)a
Co. 1: 2  1011 (2) Co. 1: 2  1011 (2)
5  1011 (10)
Co. 1: 5  1012 (5)
Co. 2: 5.0  1012 (3) Co. 2: 1  1012 (3) Co. 2: 6  1011 (2) Co. 2: 5  1013 (5)
Co. 3: 3  1012 (2) Co. 3: 2  1012 (6)
Transgene WT WT Padua WT Padua WT
Follow up, weeks 10–52 14 7-104 166 (median) 49 (mean) 26–52
Transgene activity,
% or IU/dL
5%–20% (peak) 3–11 0.5-R25 1–6 33.7 (mean) 3–13
ALT elevations 5/6
1/2, same participant
experienced AST
elevation
2/2 in Co. 3 4/6 in co. 3
2/10, same participants
experienced AST
elevation
3/10
AST elevations not reported
1/2, same patient
experienced
ALT elevation
not reported
1/6, participant with the
highest ALT elevation
2/10, same participants
experienced ALT
elevation
No
Capsid-directed
T cell activation
4/6
yes (only reported for 1
participant in the
4  1011 gc/kg group)
2/2 in Co.3 yes, Co. 2 and 3
yes (2/2 with ALT
elevation)
0/3
Immune response
steroid responsive
no not applicable
no, possibly due to
delayed start
yes yes Yes
Loss of FIX
expression
yes, 5/6
yes, 2/2 in participants
with ALT elevations
yes, 2/2 in participants
with ALT elevations +
T cell response
yes, 4/4 participants
with ALT elevations +
T cell response
yes, 1/2 with ALT/AST
elevations + T cell
response
No
ALT, alanine aminotransferase; AST, aspartate aminotransferase; Co., cohort; FIX, factor IX; gc, genome copies; WT, wild type.
aLower doses were tested but did not result in a detectable increase in FIX activity.
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gene transfer to the eye51 or brain parenchyma.52 AAV5, which has
the least-conserved capsid sequence versus other serotypes,53 and the
non-human primate serotype AAV8,49 are among the AAV vectors
with the lowest seroprevalence of NAb in humans.50,54 The seropreva-
lence of NAb to AAV-vector serotypes also varies by geography, with a
higher prevalence of AAV2 NAbs in Africa versus other regions.54
Therefore, in terms of AAV-vector capsid choice, based on rates of
pre-existing immunity it makes sense to choose a vector serotype
with the lowest prevalence in the general population such asAAV5 or 8.
There does not appear to be an association between pre-existing NAb
and subsequent T cell responses. From the re-analysis of the AAV5-
hFIXWT trial samples, the three participants with pre-existing NAb
did not experience ALT elevations and did not develop T cell
responses.45 In agreement with these data, in other human and ani-
mal trials, pre-existing immunity does not tend to be associated
with subsequent T cell responses, and T cell responses may occur
in patients without evidence of pre-existing immunity (Table 6). In
addition, there does not appear to be a link between the presence of
NAbs and subsequent loss of factor activity as this was observed in
some trials but not others.
Pre-existing NAb to AAV-vector serotypes are a major limitation in
terms of patient access to gene therapy and so far, these patients have
been excluded from gene therapy trials.40 It is possible that sequential174 Molecular Therapy: Methods & Clinical Development Vol. 15 Decemadministration of non-cross-reacting serotypes may enable re-dosing;
as was alluded to earlier in the manuscript, this approach has been
successfully demonstrated with AAV5 and AAV1 in NHPs, but has
yet to be examined in humans.33 Also in a NHP model, pre-existing
immunity following AAV5-human embryonic alkaline phosphatase
(SEAP) treatment was bypassed by immune adsorption allowing suc-
cessful transduction with AAV5-hFIX.55 In a mouse model, co-
administration of an AAV vector with tolerogenic nanoparticles
blocked anti-AAV immune responses and allowed for effective re-
dosing.56 In the future, the use of rational design to alter AAV-vector
capsids to avoid pre-existing immunity may be an option.57 Other
potential approaches that need further investigation include better
immunosuppression regimens, using the lowest possible AAV-vector
dose to achieve efﬁcacy while minimizing immune responses,
reducing the total capsid exposure by ridding preparations of empty
capsids or conversely using empty capsids as decoys, improving
manufacturing quality, and reducing potentially immunostimulatory
contaminants.40 As therapies enter the clinic, studies examining re-
dosing will be a key area for further research.
Discussion
The choice of the most appropriate AAV vector for therapeutic gene
delivery depends on a number of factors including the prevalence of
NAb to the serotype, tissue tropism, and the risk of immunogenicity.
The ideal AAV vector, therefore, would have a low seroprevalence
and titer of NAb to allow the widest possible patient access tober 2019
Table 4. Immunogenicity of Different AAV Gene-Transfer Preparations for Hemophilia A and Porphyria
Parameter
AAV5hFVIII-SQ (Valoctocogene
Roxaparvovec)24 SPK-8011 AAV-VIII41 GO-8 AAV8-HLP-hFVIII-V3 65 rAAV2/5-PBGD42
Serotype AAV5 Not reported AAV8 AAV2/5
Dose, gc/kg (n)
6  1012 (1) 5  1011 (2) 6  1011 (1) 5  1011 (2)
2  1013 (1) 1  1012 (3) 2  1012 (2) 2  1012 (2)
6  1013 (6) 2  1012 (7) 6  1012 (2)
1.8  1013 (2)
Transgene B-domain–deleted hFVIII B-domain-deleted hFVIII
17 amino-acid peptide with six
N-linked glycosylation motifs
from the human FVIII B-domain
WT
Follow up, weeks 52 46 13–47 52
Transgene activity, % or IU/dL 2–164 13-30 7–69 subclinical
ALT elevations 8/9 (low and high)
steroids in 7/12 due to declining FVIII,
ALT elevations, or IFN-g ELISPOT
2/3 1/8 (high)
AST elevations 3/9 not reported not reported not reported
Capsid-directed T cell activation 0/9
steroids in 7/12 due to declining FVIII,
ALT, or IFN-g ELISPOT
not reported 0/8
Immune response steroid responsive no yes yes not reported
Loss of FVIII expression 1/8 with ALT elevations yes, 7/7 no not applicable
ALT, alanine aminotransferase; AST, aspartate aminotransferase; Co., cohort; FVIII, factor VIII; gc, genome copies; PBGD, porphobilinogen deaminase; WT, wild type.
Table 5. NAb Exclusion Criterion across Trials of Liver-Directed Gene
Transfer for Hemophilia
Developmental Therapeutic Neutralizing Antibody Deﬁnition
AAV5-hFIXWT
(AMT-060)
29% inhibition of transduction versus pooled
NAb-negative human sera23
SPK-9001 AAV-Spark100 neutralizing antibody titer >1:525
scAAV2/8-LP1-hFIXco
no AAV8 NAb based on an in vivo transduction
inhibition assay22
AAV5-hFVIII-SQ
(Valoctocogene
Roxaparvovec)
no detectable immunity to AAV5 established with
a cell-based transduction inhibition assay and an
assay of total AAV5 immunoglobulin24
future studies may focus on total immunoglobulin
only as positive results in the transduction
inhibition assay did not impact efﬁcacy in a non-
human primate study66
AAVrh10 > 1.567
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immune responses that impact transgene expression. More needs to
be elucidated regarding potential AAV-vector serotype-speciﬁc dif-
ferences in the intracellular processing, and transduction of that
may affect clinical outcomes in gene therapy.
For liver-directed gene transfer, a number of AAV-vector sero-
types have been trialed including AAV2, AAV5, AAV8, and
AAV10. In terms of the capsid structure, AAV5 is the most phylo-
genetically distinct vector serotype, whereas other commonly used
serotypes such AAV2 and AAV8 share over 80% homology. This
may impact the prevalence of NAb to AAV5 in the general popu-
lation, which tend to be lower with AAV5 compared with sero-
types such as AAV2 and AAV1. Pre-existing NAb to AAV can
impair transduction efﬁcacy and for certain AAV-vector serotypes
the prevalence of NAb can reach up to 60%,50 which could limit
patient access to treatment. Pre-existing NAb to AAV5 at titers
commonly observed in the general population do not appear to
affect transduction efﬁcacy, and some ongoing trials with AAV5-
based vectors will include individuals with NAb.45,47,48,58 Use of
diverse AAV-vector serotypes may also permit re-administration
in the future due to decreased likelihood of cross-reactive
antibodies raised after the ﬁrst administration. As gene therapy
becomes more established, it will be important to standardize
NAb assays and deﬁne clinically relevant levels to ensure better pa-
tient access to gene therapy.
Tropism is key to targeting gene expression to appropriate tissues and
to reduce off-target effects. There is increasing evidence elucidating
the molecular interactions that underlie tropism, and in animalMolecular Thestudies, AAV-vector capsids have been engineered to modify tropism.
However, animal models may be poorly predictive of tropism in
humans. Additionally, tropism is more difﬁcult to study in humans,
so most clinical approaches depend on a tissue-speciﬁc promoter to
drive expression. This is an area that requires signiﬁcant further study
in humans, although less invasive methods than are currently avail-
able are required to enable this.
Vector clearance is relevant due to the risk of horizontal or vertical
transmission of infectious AAV vectors, although in reality the infec-
tion risk from AAV vectors is low as they are non-pathogenic and
replication deﬁcient. Additionally, because current assays assessrapy: Methods & Clinical Development Vol. 15 December 2019 175
Table 6. Pre-existing AAV Immunity and Subsequent T Cell Responses
AAV555 rAAV2hFIX44
AAV5-
hFIXWT 23,33 SPK-900125
scAAV2/8-
LP1-hFIXco 21,22 AAV5-FVIII24 AAVrh10 62,67
Study type
non-human
primate
clinical clinical clinical clinical clinical clinical
Pre-existing immunity yes 1/2 (1:2 and 1:17) 3/10 1/10 no no yes (NAb titer < 1:5)
T cell response no
1 (not in the
participant with
pre-existing
immunity)
no
2/10 (not participants
with pre-existing
immunity)
8/10 (intermediate
and high dose
group)
no yes 6/6
Efﬁcacy in participants with
pre-existing immunity
no no yes
yes, but FIX expression
lowest (approx.
10%–15%)
not applicable not applicable yes
Loss of FIX expression over
time in participants with
pre-existing immunity
not applicable
yes, peaked at
2 weeks
no no not applicable not applicable
yes, peaked between
3-14 weeks
NAb, neutralizing antibody.
www.moleculartherapy.org
Reviewvector DNA, “shedding” data does not distinguish between vector
DNA that is part of an infectious AAV particle and vector DNA frag-
ments that have no infectious risk. Vector shedding was largely tran-
sient across clinical trials although in some studies vector shedding
was detected in some body ﬂuids up to the last endpoint. There are
initial indications that lower-dose AAV vectors may be associated
with a shorter duration of vector shedding, but this needs to be
conﬁrmed. It is also possible, however, that the duration of shedding
is similar but that in some cases the magnitude of vector DNA present
is below the limits of detection.
AAV-vector trials have largely demonstrated a modest dose response
in terms of transgene expression; however, in some trials, higher
doses have been associated with T cell mediated immune responses
and associated loss of transgene expression. Therefore, in addition
to dose, there may be inherent differences between serotypes in terms
of the type of immune responses they elicit and the doses required
to do so. For example, with scAAV2/8-LP1-hFIXco, SPK-9001,
rAAV2hFIX, and AAVrh10FIX; in some cases, liver damage indi-
cated by ALT elevations is associated with T cell immune responses
and subsequent FIX decline. With AAV5-based vectors, in contrast,
there did not appear to be an association between ALT elevations,
cytotoxic T cell responses, and reduction of FIX activity. Although
this provides an initial indication of differences in the immunoge-
nicity of AAV-vector serotypes, our understanding of immune re-
sponses to AAV vectors is still at an early stage. Additionally, there
is no standardized approach to control immune responses, e.g., by
vector dose minimization, vector design, serotype usage, and/or
prophylactic or on-demand steroids.
Conclusions
Several factors enter into the consideration of capsid choice for
treating patients with gene transfer. A balance must be struck be-
tween achieving sufﬁcient transgene expression for clinical beneﬁt
and activation of the body’s immune expression. Although dose
may be a factor, there are initial indications that there may be176 Molecular Therapy: Methods & Clinical Development Vol. 15 Deceminherent differences in immunogenicity between AAV-vector sero-
types. Evidence with each serotype is currently limited because only
tens of patients have received each construct. As gene transfer be-
comes more established in the clinic, these gaps in the evidence
base should be addressed.
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